Novartis Ag

Irm LLC

Ben Wen

Michael P Cooke

Matthew T Burger

Tetsuo Uno

Bernhard Hubert Geierstanger

Yunho Jin

Kathrin Tissot

Siew Ho Schleyer

Catrin Finner

Susan E Cellitti

Anthony E Boitano

Si Tuen Lee-Hoeflich

HongNgoc Thi Pham

Colin Fletcher

Karsten Sauer

Tim Wiltshire

Lisa Tarantino

The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Antibody drug conjugates for ablating hematopoietic stem cells

This invention provides novel methods and compositions for modulating T cell differentiation and T cell responses. The modulators are identified by screening test compounds for ability to modulate an inositol 1,4,5-trisphosphate 3-kinase (IP3K). The IP3K modulators can be further examined for their activity in modulating development of progenitor T cells (e.g., CD4/CD8double positive T cells) into mature CD4or CD8single positive T cells. Pharmaceutical compositions comprising these T cell modulators can be administered to a subject to modulate T cell immune responses, to suppress inflammations, and to treat disease conditions such as autoimmune diseases, graft rejection or allergies.

Methods and compositions for modulating T lymphocytes

Growing community of inventors

Encinitas, CA, United States of America

Ben Wen